Approximately one out seven (14%) “D2T” patients had a comorbidity such as multiple sclerosis, Inflammatory bowel disease (IBD), recurrent uveitis or solid cancer within the past five years, which serves as a contraindication for the use of anti-TNF or anti-IL-17 inhibitors. Here, IL17A is linked to inflammatory bowel disease.